We look forward to bringing you more stories and discussion on statistical methods and clinical development in the year ahead. In case you missed any of our popular stories from 2014, here are the posts that generated the most buzz in the preceding year.
In this interview style blog post, we we got a roundtable of our consultants together to help a customer who was curious but anxious about adaptive designs.
The Cytel ClipLab is one of Cytel's educational initiatives. As the pharmaceutical industry changes, new questions arise about educating the next generation of researchers, clinicians and programmers. This post looks at the ClipLab approach to preparing recent graduates for successful careers in the industry.
This post was the last in a three part series on data management and biostatistics. It looked specifically at the idea of statistical innovation in the field of data management, such as that currently used in risk-based monitoring.
All consulting requires versatile consultants who can bring insight and innovation to a variety of challenges in strategic development. Yet the nature of the pharmaceutical industry is that it requires participants to be specialists, which in turn takes time and practice and leaves little room to develop versatility. This post examines how statistical consultants can still cultivate versatility without compromising the quality and rigour expected of specialists.
This post introduces a presentation by Professor LJ Wei (Harvard School of Public Health), in which he explores 11 standards he believes professional biostatisticians should learn to question. Presentation slides are attached.
Believe it or not, there is a 10 step procedure to determining whether your next trial should be adaptive. It is outlined in great detail in the Cytel Whitepaper on Adaptive Trial Designs. For a simple overview of the 10 steps click the link to this post.
The 'Keep It Simple' Rule in trial design, is a rule of thumb which encourages simple statistical designs for clinical trials. In this post we argue that in actual trial implementation, desgins that 'Keep It Simple' might face more financial and operational challenges than complicated designs. Instead, we argue for a 'Keep It Flexible' rule that overcomes these logistical challenges.
Rare disease drug development is one place where Bayesian methods have extraordinary potential to make a difference. Our guest blogger Dr. Sofia Villar (MRC Biostats) presents the case for using 'Multi-Armed Bandit' designs for rare disease drug development.
Our East 6.3 launch party at the Seaport Hotel in Boston last summer had some very interesting guests, including the Goode Reverend Thomas Bayes (18th century father of Bayesian statistics.) Click and take a look!
A clear indication that even the most serious experts love a good cartoon, this Cytel animation on Bayesian methods for dose-escalation was one of the most viewed posts from 2014.